Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GMRx4
- Development stage
- Phase 4
- Lead developer
- George Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GMRx4 is a novel proprietary ultra-low-dose triple combination candidate developed by George Medicines as a first-line treatment for type 2 diabetes mellitus. The drug is a single-pill formulation containing three best-in-class agents: metformin XR (350 mg), the SGLT2 inhibitor dapagliflozin (2.5 mg), and the DPP-4 inhibitor sitagliptin (17.5 mg). Each component is formulated at a dose below the lowest currently approved strength, aiming to provide a synergistic therapeutic effect with improved safety and tolerability. GMRx4 is currently in Phase II clinical development, specifically being evaluated in the PiVOT trial for newly diagnosed patients.
- Other names
- GMRx-4 IR polypillGMRx4 IR polypillGMRx 4 IR polypillmetformin + dapagliflozin + sitagliptin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)DPP-4 (Dipeptidyl Peptidase-IV)ND1 (Mitochondrial electron transport chain complex I)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on GMRx4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GMRx4.